Prolongation of tumor volume doubling time (midDT) is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine-refractory differentiated thyroid cancer selected for molecular targeted therapy
Clinical Endocrinology Feb 09, 2019
Sabra MM, et al. - Researchers analyzed the data to evaluate the ability of molecular targeted therapy (MTT) to influence tumor volume doubling time (TVDT) and disease-specific survival (DSS) in cases with lung metastasis from radioactive iodine-refractory progressive thyroid cancer. They recorded the median survival of 2.9 years after MTT start. They noticed a prolonged lung average tumor volume doubling time (midDT) > 3 years in 75% of cases with baseline midDT < 1 year and 100% of patients with midDT 1-3 years. In patients with rapidly progressive thyroid cancer, they found the median survival of 4.5 years in those with MTT- achieved midDT > 3 years, as compared to 2.3 years and 0.7 years in those with MTT-achieved midDT of 1-3 years and MTT-achieved midDT < 1year respectively.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries